[Effect of the nomenclature of non-alcoholic fatty liver disease on diagnosis and treatment of fatty liver disease concomitant with other liver diseases].

Fatty liver disease (FLD) is one of the major causes of chronic liver disease worldwide. With the increasing incidence of obesity and metabolic syndrome worldwide, FLD concomitant with other liver diseases is becoming more common, and multiple etiological overlap is associated with poor disease prognosis. Therefore, FLD concomitant with other liver diseases is a clinical concerning issue. Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of disease continuum from non-alcoholic fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH), and relative end stage liver disease, excluding other factors that may lead to fatty liver disease such as excessive alcohol consumption et. al. Following the nomenclature of NAFLD with metabolic associated fatty liver disease (MAFLD), an international panel of experts proposed a new name in June 2023 as Metabolic dysfunction - associated steatotic liver disease (MASLD), replacing the word "fatty" with "steatotic," The effect of lipid toxicity on FLD progression was highlighted. Compared with the concept of MAFLD, the disease spectrum of MASLD is broader, and the etiology and mechanism are more clear. The nomenclature of FLD brings some influence to the diagnosis and treatment of chronic liver diseases concomitant with FLD, including chronic hepatitis B, alcoholic fatty liver disease and genetic metabolic diseases. This article reviews the influence of renaming FLD on the diagnosis and treatment of FLD concomitant with other etiologies caused liver diseases.脂肪肝是当前世界范围内慢性肝病的主要原因之一。随着全球范围内肥胖和代谢综合征发病率的增加，FLD重叠其他肝病愈加常见，多病因重叠与较差的疾病预后相关，因此，脂肪肝合并其他肝病是临床中需要关注的问题之一。非酒精性脂肪性肝病（NAFLD）包涵了一组除过量饮酒等其他可能导致脂肪肝因素外的疾病谱，包括单纯肝脂肪变性（NAFL）到非酒精性脂肪性肝炎（NASH）及相关终末期肝病。继提出将NAFLD更名为代谢相关脂肪性肝病（MAFLD）专家建议之后，2023年6月国际专家组提出代谢功能障碍相关脂肪变性肝病新命名，将MAFLD更名为代谢相关脂肪性肝病（MASLD），以"steatotic"取代"fatty"一词，突出脂毒性对脂肪肝进展的影响。相比NAFLD的命名，MASLD涵盖疾病谱更广泛、病因及机制更加明确。脂肪肝更名给酒精性肝病、慢性乙型肝炎及遗传代谢病等慢性肝病合并脂肪肝患者的诊治带来了一定程度的影响。本文针对脂肪肝更名对脂肪肝合并其他肝病诊治的影响进行述评。.